Susan Bhatt

Susan Bhatt investigates the combination of dendritic cell vaccines with immune checkpoint inhibitors, demonstrating that DC vaccination can prime anti-tumor T cell responses that are then potentiated by PD-1 blockade. Her clinical trials have shown improved response rates with sequential DC vaccine followed by checkpoint immunotherapy compared to either approach alone. She has identified biomarkers predicting which patients benefit from DC-IO combinations. Her translational research is defining the optimal integration of DC vaccines with modern immunotherapy.